Holen Sie sich die Stockscreener-App
0.22
10.57%
-0.026
Schlusskurs vom Vortag:
$0.246
Offen:
$0.252
24-Stunden-Volumen:
12.99M
Relative Volume:
6.13
Marktkapitalisierung:
$4.95M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-31.59M
KGV:
-0.0843
EPS:
-2.61
Netto-Cashflow:
$-26.75M
1W Leistung:
-47.90%
1M Leistung:
-72.84%
6M Leistung:
-78.00%
1J Leistung:
-88.42%
1-Tages-Spanne:
$0.2131
$0.252
1-Wochen-Bereich:
$0.1605
$0.3111
52-Wochen-Spanne:
$0.1605
$2.48
Palatin Technologies Inc. Stock (PTN) Company Profile
Firmenname
Palatin Technologies Inc.
Sektor
Branche
Telefon
609-495-2200
Adresse
Cedar Brook Corporate Center, 4B Cedar Brook Drive, Cranbury, NJ
Vergleichen Sie PTN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTN
Palatin Technologies Inc.
|
0.22 | 4.95M | 7.10M | -31.59M | -26.75M | -2.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Palatin Technologies Inc. Stock (PTN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2015-06-05 | Bestätigt | Canaccord Genuity | Buy |
| 2015-01-12 | Bestätigt | ROTH Capital | Buy |
| 2012-05-23 | Eingeleitet | Noble Financial | Buy |
| 2007-01-23 | Eingeleitet | Next Generation | Buy |
Palatin Technologies Inc. Aktie (PTN) Neueste Nachrichten
Palatin’s obesity study shows promise in appetite control By Investing.com - Investing.com Canada
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide - The Malaysian Reserve
Dry Eye Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Palatin Technologies, Novaliq, mc2 therapeutics - The Globe and Mail
Palatin (PTN) Reports Positive Phase 2 Study Results for Obesity Treatment | PTN Stock News - GuruFocus
Palatin’s obesity study shows promise in appetite control - Investing.com
Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide | PTN Stock News - GuruFocus
Breakthrough Obesity Treatment Shows 71% Appetite Control, Blocks Post-Treatment Weight Rebound - Stock Titan
What Analysts Think About Palatin Technologies Inc (AMEX: PTN)’s Potential Raise - stocksregister.com
Palatin Appeals NYSE American Notice of Delisting - Kilgore News Herald
Palatin Technologies (PTN) Appeals NYSE Delisting Decision | PTN Stock News - GuruFocus
Palatin Appeals NYSE American Notice of Delisting | PTN Stock Ne - GuruFocus
Palatin Appeals NYSE Delisting, Pursues Financing And Partnerships To Regain Compliance - Nasdaq
Palatin contests NYSE American delisting notice By Investing.com - Investing.com South Africa
Palatin Appeals NYSE American Notice of Delisting | PTN Stock News - GuruFocus
Palatin contests NYSE American delisting notice - Investing.com
Palatin Appeals NYSE American Notice Of Delisting - marketscreener.com
Palatin Launches Bold Defense Against NYSE Delisting: Multi-Strategy Rescue Plan Revealed - Stock Titan
Stock Slump: Eyewear Innovator And Tech Firms Face Market Hits - Finimize
Palatin Technologies (PTN) Faces NYSE American Delisting Proceedings - GuruFocus
Palatin (PTN) Faces Delisting Proceedings from NYSE American | P - GuruFocus
Palatin to Present Positive Phase 2b Data for Melanocortin Agoni - GuruFocus
Palatin Technologies faces potential NYSE American delisting By Investing.com - Investing.com Canada
Palatin reports promising kidney disease treatment results By Investing.com - Investing.com South Africa
Palatin Technologies shares fall as it receives NYSE American delisting notice - MSN
Palatin Technologies faces potential NYSE American delisting - Investing.com Australia
Palatin Technologies, Inc. Announces Receipt Of NYSE American Notice Of Delisting And Intention To Appeal - MarketScreener
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN) - Business Wire
Palatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to Appeal - PR Newswire
Palatin reports promising kidney disease treatment results - Investing.com Australia
Palatin Technologies Reports Positive Data From Phase 2b BREAKOUT Study - Nasdaq
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting - Kilgore News Herald
Indo-Asian News Service - Indo-Asian News Service (IANS)
Palatin Technologies stock hits 52-week low at $0.45 - Investing.com
Palatin Technologies stock hits 52-week low at $0.45 By Investing.com - Investing.com India
Palatin touts Phase II obesity study results - The Pharma Letter
Palatin study shows weight loss with new drug combo By Investing.com - Investing.com Canada
Palatin Technologies’ UC Treatment Shows Remarkable 78% Clinical Response Rate in Phase 2 Topline Data – Potential Game-Changer for Millions Suffering from Ulcerative Colitis (NYSE: PTN) - Barchart.com
Palatin Technologies' Obesity Drug Co-Administered With Eli Lilly's Blockbuster Drug Shows 4.4% Reduction In Weight - Benzinga
Palatin study shows weight loss with new drug combo - Investing.com
Breakthrough Obesity Treatment: New Drug Combo Achieves 4.4% Weight Loss in Clinical Trial - Stock Titan
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study - The Malaysian Reserve
Palatin reported promising results in trial for ulcerative colitis treatment - MSN
PTN stock touches 52-week low at $0.67 amid market challenges - Investing.com Australia
PTN stock touches 52-week low at $0.67 amid market challenges By Investing.com - Investing.com South Africa
Palatin’s UC therapy prompts clinical remission in a third of patients - Yahoo
Palatin Technologies' Ulcerative Colitis Drug Candidate Shows Positive Results in Phase 2 Study - MarketScreener
Palatin reported promising results in trial for ulcerative colitis treatment (PTN:NYSE) - Seeking Alpha
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 - The Malaysian Reserve
Palatin Technologies Touts Positive Results From Mid-Stage Study For Experimental Drug For Ulcerative Colitis, Halts Patients Enrollment Citing Strategic Focus - Benzinga
Finanzdaten der Palatin Technologies Inc.-Aktie (PTN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):